Spanlastics as a Potential Platform for Enhancing the Brain Delivery of Flibanserin: In Vitro Response-Surface Optimization and In Vivo Pharmacokinetics Assessment

Flibanserin was licensed by the United States Food and Drug Administration (FDA) as an oral non-hormonal therapy for pre-menopausal women with inhibited sexual desire disorder. However, it suffers from susceptibility to first-pass metabolism in the liver, low aqueous solubility, and degradation in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Alharbi, Waleed S., Hareeri, Rawan H., Bazuhair, Mohammed, Alfaleh, Mohamed A., Alhakamy, Nabil A., Fahmy, Usama A., Alamoudi, Abdullah A., Badr-Eldin, Shaimaa M., Ahmed, Osama A., AlGhamdi, Shareefa A., Naguib, Marianne J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786754/
https://www.ncbi.nlm.nih.gov/pubmed/36559120
http://dx.doi.org/10.3390/pharmaceutics14122627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786754/
https://www.ncbi.nlm.nih.gov/pubmed/36559120
http://dx.doi.org/10.3390/pharmaceutics14122627

Ejemplares similares